Drug intelligence / Profile preview

TLN-372 + cetuximab

Development stage: Unknown
Lead developer: Treeline Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

TLN-372 + cetuximab is a combination therapy being developed by Treeline Biosciences for the treatment of advanced solid tumors harboring KRAS mutations. TLN-372 is a small molecule, pan-KRAS inhibitor designed for deep and continuous inhibition of various KRAS mutant isoforms. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The combination aims to overcome potential resistance mechanisms and enhance anti-tumor activity by simultaneously inhibiting the KRAS pathway and its upstream activator, EGFR. It is currently being evaluated in a Phase 1 clinical trial.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on TLN-372 + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLN-372 + cetuximab.

Explore the full profile